Metadata
Author: ParaCrawl Corpus
Data
English[en]
Defibrotide is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients who have hepatic SOS/VOD with renal or pulmonary dysfunction after HSCT.
Spanish[es]
La FDA de los Estados Unidos aprobó el uso de la defibrotida en pacientes con SOS/EVO que presentan disfunción renal o pulmonar después de un TCMH.